TABLE I—Continued

States/populations/areas to be served	Approximate funding available	Application due date	Approx. grant funding date
Region IX:			
Navajo Nation	640,000	03/01/07	07/01/07
Commonwealth of the Northern Mariana Islands	170,000	09/01/06	01/01/07
Federated States of Micronesia	411,000	03/01/07	07/01/07
Nevada, Washoe County	708,000	03/01/07	07/01/07
Region X:			
Alaska	420,000	03/01/07	07/01/07
Oregon	2,452,000	03/01/07	07/01/07
Idaho	1,568,000	03/01/07	07/01/07
Washington	3,240,000	09/01/06	01/01/07
Washington, Seattle area	159,000	03/01/07	07/01/07

Dated: July 19, 2006.

Evelyn M. Kappeler,

Acting Director, Office of Population Affairs.

[FR Doc. E6–11963 Filed 7–25–06; 8:45 am]

BILLING CODE 4150–34–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the National Coordinator; American Health Information Community Biosurveillance Data Steering Group Meeting

ACTION: Announcement of meeting.

SUMMARY: This notice announces the third meeting of the American Health Information Community Biosurveillance Data Steering Group in accordance with the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App.).

DATES: August 8, 2006 from 2 p.m. to 4 p.m.

ADDRESSES: Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090 (you will need a photo ID to enter a Federal building).

FOR FURTHER INFORMATION CONTACT: *http://www.hhs.gov/healthit/ahic.html.*

SUPPLEMENTARY INFORMATION: The meeting will be available via Internet access. Go to *http://www.hhs.gov/healthit/ahic.html* for additional information on the meeting.

Dated: July 19, 2006.

Judith Sparrow,

Director, American Health Information Community, Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology.

[FR Doc. 06–6485 Filed 7–25–06; 8:45am]

BILLING CODE 4150–24–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Advisory Committee on Blood Safety and Availability

AGENCY: Office of Public Health and Science, Office of the Secretary, DHHS.

ACTION: Notice.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood Safety and Availability (ACBSA) will hold a meeting. The ACBSA will meet to review progress and solicit additional input regarding numerous recommendations made during the past year, specifically biovigilance of blood components and its derivatives, cells, tissues, and organs. Vigilance is recognized as a necessary step in monitoring outcomes in a quality assurance process toward the goal of providing safe and available biological products (i.e., blood components and derivatives, cells, tissues and organs) and improvement of care of the donor and recipient. Elements necessary for vigilant surveillance are detection, analysis, reporting, utilizations, research, education, and management of outcomes, including emerging or re-emerging infectious and non-infectious events of transfusion and/or transplantation, will be discussed.

DATES: The meeting will take place Wednesday, August 30 and Thursday, August 31, 2006 from 9 a.m. to 5 p.m.

ADDRESSES: Marriott Crystal Gateway, 1700 Jeff Davis Highway, Arlington, VA 22202.

FOR FURTHER INFORMATION CONTACT: Jerry A. Holmberg, PhD, Executive Secretary, Advisory Committee on Blood Safety and Availability, Office of Public Health and Science, Department of Health and Human Services, 1101 Wootton Parkway, Room 250, Rockville, MD 20852, (240) 453–8809, fax (240) 453–8456, e-mail *jholmberg@osophs.dhhs.gov.*

SUPPLEMENTARY INFORMATION: Public comment will be solicited at the meeting and will be limited to five minutes per speaker. Individuals who wish to present comments to the Committee should contact the Executive Secretary to register no later than close of business on August 25, 2006. Individuals who wish to have printed material distributed are encouraged to provide thirty (30) copies to the Executive Secretary no later than close of business August 25, 2006. Likewise, those who wish to utilize electronic data projection to the Committee must submit their materials to the Executive Secretary prior to close of business August 25, 2006.

Dated: July 20, 2006.

Jerry A. Holmberg,

Executive Secretary, Advisory Committee on Blood Safety and Availability.

[FR Doc. E6–11962 Filed 7–25–06; 8:45 am]

BILLING CODE 4150–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006O–0231]

Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Sunscreen Ingredient

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of eligibility; request for data and information.

SUMMARY: The Food and Drug Administration (FDA) is announcing a call-for-data for safety and effectiveness information on the following condition as part of FDA's ongoing review of over-the-counter (OTC) drug products: Diethylhexyl butamido triazone, up to 3 percent, as a sunscreen single active

ingredient and in combination with other sunscreen active ingredients. FDA reviewed a time and extent application (TEA) for this condition and determined that it is eligible for consideration in our OTC drug monograph system. FDA will evaluate the submitted data and information to determine whether this condition can be generally recognized as safe and effective (GRASE) for its proposed OTC use.

DATES: Submit data, information, and general comments by October 24, 2006.

ADDRESSES: You may submit comments, identified by Docket No. 2006O–0231, by any of the following methods:

Electronic Submissions

Submit electronic comments in the following ways:

- Federal eRulemaking Portal: *http://www.regulations.gov*. Follow the instructions for submitting comments.
- Agency Web site: *http://www.fda.gov/dockets/ecomments*. Follow the instructions for submitting comments on the agency Web site.

Written Submissions

Submit written submissions in the following ways:

- FAX: 301–827–6870.
- Mail/Hand delivery/Courier [For paper, disk, or CD–ROM submissions]: Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

To ensure more timely processing of comments, FDA is no longer accepting comments submitted to the agency by e-mail. FDA encourages you to continue to submit electronic comments by using the Federal eRulemaking Portal or the agency Web site, as described in the *Electronic Submissions* portion of this paragraph.

Instructions: All submissions received must include the agency name and Docket number for this rulemaking. All comments received may be posted without change to *http://www.fda.gov/ohrms/dockets/default.htm*, including any personal information provided. For additional information on submitting comments, see the ''Request for Comments, Data, and Information'' heading of the **SUPPLEMENTARY INFORMATION** section of this document.

Docket: For access to the docket to read background documents or comments received, go to *http://www.fda.gov/ohrms/dockets/default.htm* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Michael L. Koenig, Center for Drug Evaluation and Research (mail stop 5411), Food and Drug Administration, bldg. 22, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–2090.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of January 23, 2002 (67 FR 3060), FDA published a final rule establishing criteria and procedures for additional conditions to become eligible for consideration in the OTC drug monograph system. These criteria and procedures, codified in § 330.14 (21 CFR 330.14), permit OTC drugs initially marketed in the United States after the OTC drug review began in 1972 and OTC drugs without any marketing experience in the United States to become eligible for FDA's OTC drug monograph system. The term ''condition'' means an active ingredient or botanical drug substance (or a combination of active ingredients or botanical drug substances), dosage form, dosage strength, or route of administration, marketed for a specific OTC use (§ 330.14(a)). The criteria and procedures also permit conditions that are regulated as cosmetics or dietary supplements in foreign countries but that would be regulated as OTC drugs in the United States to become eligible for the OTC drug monograph system.

Sponsors must provide specific data and information in a TEA to demonstrate that the condition has been marketed for a material time and to a material extent to become eligible for consideration in the OTC drug monograph system. When the condition is found eligible, FDA publishes a notice of eligibility and request for safety and effectiveness data for the proposed OTC use. The TEA that FDA reviewed (Ref. 1) and FDA's evaluation of the TEA (Ref. 2) have been placed on public display in the Division of Dockets Management (see **ADDRESSES**) under the docket number found in brackets in the heading of this document. Information deemed confidential under 18 U.S.C. 1905, 5 U.S.C. 552(b), or 21 U.S.C. 331(j) (section 301(j) of the Federal Food, Drug, and Cosmetic Act) was deleted from the TEA before it was placed on public display.

II. Request for Comments, Data, and Information

FDA determined that the information submitted in this TEA satisfies the criteria of § 330.14(b). FDA will evaluate diethylhexyl butamido triazone, up to 3 percent, as a sunscreen single active ingredient and in combination with other existing monograph sunscreen active ingredients, for inclusion in the monograph for OTC sunscreen drug products (part 352 (21 CFR part 352)). Accordingly, FDA invites all interested persons to submit data and information, as described in § 330.14(f), on the safety and effectiveness of this active ingredient for this use so that FDA can determine whether it can be GRASE and not misbranded under recommended conditions of OTC use. Additional data should be included to establish the safety and effectiveness of sunscreen drug products containing a combination of diethylhexyl butamido triazone with other existing sunscreen monograph active ingredients in § 352.10.

The TEA did not include an official or proposed United States Pharmacopeia-National Formulary (USP–NF) drug monograph for diethylhexyl butamido triazone. According to § 330.14(i), sponsors must include an official or proposed USP–NF monograph as part of the safety and effectiveness data for this ingredient.

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments, data, and information. Submit three copies of all comments, data, and information. Individuals submitting written information or anyone submitting electronic comments may submit one copy. Submissions are to be identified with the docket number found in brackets in the heading of this document and may be accompanied by supporting information. Received submissions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Information submitted after the closing date will not be considered except by petition under 21 CFR 10.30.

III. Marketing Policy

Under § 330.14(h), any product containing the condition for which data and information are requested may not be marketed as an OTC drug in the United States at this time unless it is the subject of an approved new drug application or abbreviated new drug application.

IV. References

The following references are on display in the Division of Dockets Management (see **ADDRESSES**) and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday.

1. TEA for diethylhexyl butamido triazone submitted by 3V, Inc., on September 16, 2005.

2. FDA's evaluation and comments on the TEA for diethylhexyl butamido triazone.

Dated: July 14, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E6–11874 Filed 7–25–06; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HOMELAND SECURITY

Transportation Security Administration

Aviation Security Advisory Committee Meeting

AGENCY: Transportation Security Administration (TSA), DHS.

ACTION: Notice of meeting.

SUMMARY: This notice announces a telephonic meeting of the Aviation Security Advisory Committee (ASAC).

DATES: The meeting will take place on August 16, 2006, from 2:30 p.m. to 3:30 p.m., Eastern time.

ADDRESSES: The meeting will be held by telephonic conference call. Dial-in instructions are set forth in the **SUPPLEMENTARY INFORMATION** section below.

FOR FURTHER INFORMATION CONTACT: Richard Swigart, Office of Transportation Sector Network Management (TSA–28), TSA Headquarters, 601 South 12th Street, Arlington, VA 22202; telephone 571–227–3719, e-mail *richard.swigart@dhs.gov.*

SUPPLEMENTARY INFORMATION: This meeting is announced pursuant to section 10(a)(2) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.). The agenda for the meeting will include presentation of the report and recommendations of the Baggage Screening Investment Study (BSIS) working group.

This meeting, from 2:30 p.m. to 3:30 p.m., is open to the public but telephonic conferencing capacity is limited. Members of the public who wish to monitor the discussion may dial into this telephonic meeting by dialing (800) 988–9352. At the prompt, provide the conference code ''ASAC'' (pronounced ''*A*-sack''). Parties calling from locations outside the United States must contact the person listed under the heading **FOR FURTHER INFORMATION CONTACT**, for international calling instructions.

Persons desiring a copy of the working group's report may request it by contacting the person listed under the heading **FOR FURTHER INFORMATION CONTACT**.

Members of the public must make advance arrangements to present oral statements at this ASAC meeting. Written statements may be presented to the committee by providing copies of them to the Chair prior to the meeting. Comments may be sent to the person listed under the heading **FOR FURTHER INFORMATION CONTACT**. Anyone in need of assistance or a reasonable accommodation for the meeting should contact the person listed under the heading **FOR FURTHER INFORMATION CONTACT**.

Issued in Arlington, Virginia, on July 21, 2006.

John Sammon,

Assistant Administrator for Transportation Sector Network Management.

[FR Doc. E6–11935 Filed 7–25–06; 8:45 am]

BILLING CODE 9110–05–P

DEPARTMENT OF HOMELAND SECURITY

Transportation Security Administration

[Docket No. TSA–2006–25335]

RIN 1652–ZA08 [Corrected]

Privacy Act of 1974: System of Records; National Finance Center (NFC) Payroll Personnel System; Correction

AGENCY: Transportation Security Administration, DHS.

ACTION: Notice to establish a new system of records; request for comments; correction.

SUMMARY: This document makes a correction to the notice published in the **Federal Register** on July 17, 2006, establishing a new system of records under the Privacy Act of 1974. The new system is known as the National Finance Center Payroll Personnel System (DHS/TSA 022) and is to be used to reflect the Transportation Security Administration's (TSA) migration from its legacy payroll system (the Department of Transportation's Integrated Personnel and Payroll System (IPPS), Consolidated Uniform Payroll System (CUPS), and Consolidated Personnel Management Information System (CPMIS)) to the Department of Agriculture's National Finance Center (NFC). TSA inadvertently transposed the digits in the RIN number in the document headings section. This document corrects this number.

DATES: Effective July 26, 2006.

FOR FURTHER INFORMATION CONTACT: Marisa Mullen, Office of the Chief Counsel (Regulations), TSA–2, Transportation Security Administration, 601 South 12th Street, Arlington, VA 22202–4220; telephone (571) 227–2706.

SUPPLEMENTARY INFORMATION:

Background

On July 17, 2006, TSA published a notice in the **Federal Register** (71 FR 40530), establishing a new system of records under the Privacy Act of 1974, known as the National Finance Center Payroll Personnel System (DHS/TSA 022). TSA inadvertently transposed the digits in the RIN number in the document headings section. This document corrects this number from RIN 1652–AZ08 to RIN 1652–ZA08.

Correction

In notice FR Doc. E6–11235, published on July 17, 2006 (71 FR 40530), make the following correction:

On page 40530, column one, line five, in the document headings section, remove the words ''RIN 1652–AZ08'' and add in its place the words ''RIN 1652–ZA08''.

Issued in Arlington, Virginia, on July 19, 2006.

Mardi Ruth Thompson,

Deputy Chief Counsel for Regulations.

[FR Doc. E6–11903 Filed 7–25–06; 8:45 am]

BILLING CODE 9110–05–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Citizenship and Immigration Services

Agency Information Collection Activities: Extension of a Currently Approved Information Collection; Comment Request

ACTION: 60-day notice of information collection under review: Interagency Record of Individual Requesting Change/Adjustment To or From A or G Status or Requesting A, G, or NATO Dependent Employment Authorization; Form I–566, OMB Control Number 1615–0027.

The Department of Homeland Security, U.S. Citizenship and Immigration Services has submitted the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for sixty days until September 25, 2006.

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated